Phase 4 N=220 Losartan Effects on Emphysema Progression
Emphysema
Primary: Change in Mean pct950 — 1.35; 0.66 percentage of voxels — p=0.133
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema
Emphysema
Primary: Percent Change in FEV1 at 6 Months — 12.745; -2.604 percent change from baseline
N/A N=190 Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)
Emphysema
Primary: Forced Expiratory Volume in 1-second (FEV1) — 61; 10 Participants
Phase 4 N=180 Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
Alpha1-proteinase Inhibitor Deficiency · Emphysema
Primary: Annual Rate of Change in Lung Density — -1.50; -2.12; -1.45; -2.19 g/L per year — p=0.029
Phase 4 N=19 Hypoxic Pulmonary Vasoconstriction Pilot Study
Emphysema
Primary: Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration — 0.37; 0.42 coefficient of variation — p=<0.05
Phase 2 N=77 Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
Alpha 1-Antitrypsin Deficiency
Primary: The Progression Rate of Emphysema Determined by Change in 15th Percentile of Lung Density Measured by Annual CT Scan of the Whole Lung — 47.980; 45.477; 45.085; 41.354…
N/A N=463 Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema
Primary: Absolute Change From Baseline at Week 156 in Adjusted Lung Density (ALD) Based on Percentile Density at 15% (PD15) Adjusted for Lung Volume — -0.27; -3.15; -5.04; -4.74…
Phase 2 N=118 Prostaglandin Inhibition for Emphysema
Emphysema
Primary: Will Ibuprofen, 600 mg Three Times Daily, Decrease PGE Concentration in the Alveolar Portion of BAL Fluid in Subjects With Emphysema in Comparison to Placebo? — 0.003…
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
N/A N=93 Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study
COPD Patients With Homogeneous Emphysema · Endoscopic Lung Volume Reduction With Endobronchial Valve
Primary: Percentage Change in Forced Expiratory Volume in 1 s (FEV1) (ITT Population) — 13.7; -3.2 percent change
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
N/A N=56 Macrophage Phagocytosis in COPD
Chronic Obstructive Pulmonary Disease · Emphysema · Chronic Bronchitis
Primary: Phagocytosis of H. Influenzae Concentration — 0.042; 0.042; 0.014; 0.06 relative fluorescence unit — p=0.05
Phase 2 N=18 PEEP as Rescue Therapy for Asthmatics With Elevated BMI
Asthma
Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L
Phase 2 N=337 Tezepelumab COPD Exacerbation Study
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. — 1.75; 2.11 exacerbations per year — p=0.1042
N/A N=9 Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy
Emphysema
Primary: Count of Patients With Grade 3 or Higher Adverse Events. — 3 Participants
N/A N=252 Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
COPD
Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001
Phase 2 N=48 Effect of BIBW 2948 BS in COPD
Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic
Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305
Phase 2 N=171 Imaging Regional Lung Defect Severity
COPD
Primary: Gas Trapping Measured During Washout of the Perfluorinated Gas Mixture. — 0.718; 0.541; 0.308; 0.451 percentage of total lung volume — p=<0.0001
Phase 2 N=17 Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies
Chronic Obstructive Pulmonary Disease · Emphysema
Primary: Percent Change of Circulating Anti-GRP78 IgG Levels — -17.0; -2.6 % change
Phase 2 N=282 A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
COPD
Primary: Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.0009; 0.1055; 0.1333; 0.1336 liters — p=0.0043
N/A N=133 Chronic Obstructive Pulmonary Disease Markers and Prognosis
Chronic Obstructive Pulmonary Disease
Primary: Forced Expiratory Volume in the First Second (FEV1) — 54; 54 Percentage predicted — p=0.09
N/A N=746 Pulmonary Embolism as a Cause of COPD Exacerbations
Pulmonary Embolism · Chronic Obstructive Pulmonary Disease
Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants
Phase 4 N=26 Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline of Systemic Markers of Bone Metabolism (C-terminal Peptide of Type 1 Collagen (CTx) and Amino-terminal Propeptide of Type-1 Procollagen (P1NP))…
Phase 2 N=15 Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency · Emphysema · Chronic Obstructive Pulmonary Disease
Primary: Pulmonary Microvascular Blood Flow, Mean — 36.9; 35.1 mL blood/minute per 100mL lung — p=0.692
N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Phase 2 N=15 Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
N/A N=27 Doxycycline for COPD in HIV-Infected Patients
HIV · Chronic Obstructive Pulmonary Disease (COPD) · Emphysema
Primary: Safety of Doxycycline, as Measured by the Number of Subjects With Any Treatment-related Adverse Events. — 3; 1 Participants
Phase 4 N=30 Dynamic Hyperinflation and Tiotropium
COPD
Primary: Bronchodilator Response:Peak FEV1(L)(Forced Expiratory Volume in One Second)- — 1.74; 1.82 liters — p=0.027
Phase 4 N=584 Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Pre-dose FEV1 — 1.079; 1.009 Ratio — p=<.0001
N/A N=182 Active for Life: Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Time Spent in Physical Activity as Measured by Upright Time (Minutes Per Day) Monitored by ActivPal Monitor — 278; 269; 293; 285 minutes per day